Brainstorm Cell Therapeutics Inc. (BCLI) - Expected Profit
Brainstorm Cell (BCLI) strictly adheres to sanitary regulations when disposing of biomaterials in its laboratories. Its resilience relies on the success of the NurOwn therapy for ALS and FDA approval. Positive clinical data for Alzheimer's treatment will serve as a growth catalyst. The company's future profitability metric reflects the dynamics of expected earnings, where the indicator value is 0.04.
Analytical breakdowns for Brainstorm Cell Therapeutics Inc. (BCLI)
- share price and consensus valuation forecast:
- market capitalization indicators:
- company book value details:
- company total debt and liquidity indicators:
Debt to Equity Brainstorm Cell|BCLI - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Brainstorm Cell Therapeutics, Inc.|BCLI - Company Total Debt Obligations|Debt to Book Value BrainStorm Cell Therapeutics|BCLI - Amount of Long-Term Liabilities|Company Short-Term Debt BrainStorm Cell Therapeutics|Quick Liquidity brainstorm-cell.com
- earnings and valuation multiples information:
BCLI - Final Profit|Expected Profit Brainstorm Cell|BCLI - Price to Earnings Ratio|Projected Price to Earnings BrainStorm Cell Therapeutics|BCLI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple BrainStorm Cell Therapeutics|BCLI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BrainStorm Cell Therapeutics|BCLI - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Net earnings per share growth forecast for next year Brainstorm Cell
Initial company analysis:Brainstorm Cell
The development of ALS therapy in Israel and the US drives the forward earnings chart for Brainstorm Cell (BCLI). This metric consolidates market expectations for the business's future cash flows. The indicator measures the gap between management's optimism and the real-time valuation of the NurOwn platform. This analysis makes it possible to identify asset overvaluation before a correction occurs. The long-term consensus reflects investor confidence in the commercialization of cellular technologies.
Direct competitors
BIIB (Biogen Inc.) - Projected Future Earnings|Expected Profit NBIX|Expected Profit Regencell Bioscience Holdings Limited (RGC)|AXSM (Axsome) - Expected Net Income|Projected Future Earnings ACAD (ACADIA Pharmaceuticals Inc)|Projected Future Earnings Xenon Corp XENE|Viking Therapeutics - Projected Future Earnings|Company Profit Forecast supernus.com SUPN|Catalyst Pharmaceuticals, Inc. (CPRX) - Expected Profit|Net Profit Forecast DNLI|Expected Profit Harmony Pharma|Biohaven Corp (BHVN) - Company Profit Forecast|Future Profit AMLX (Amylyx Pharmaceuticals)|Future Net Profit TRVI|Expected Profit Praxis Precision Medicines, Inc. PRAX|Anavex (AVXL) - Expected Net Profit|CBLL - Expected Profit|Expected Net Income PRTA (Prothena Corporation)|alector.com (ALEC) - Expected Profit|Future Profit annexonbio.com|Future Profit OMER|NGNE: Expected Net Income|Projected Future Earnings ACIU|Future Profit Voyager Corp VYGR|Projected Future Earnings NMRA (Neumora Therapeutics)|scilexholding.com (SCLX) - Expected Net Profit|TVGN - Expected Profit|ACOG: Expected Profit|Cognition Therapeutics, Inc. (CGTX) - Expected Profit|IKT (Inhibikase Pharma) - Expected Profit|SAVA (Cassava Sciences, Inc.) - Projected Future Earnings|Expected Profit ASRT|Projected Future Earnings COYA|Future Profit vistagen.com VTGN|Expected Profit Ovid Therapeutics OVID|Acumen Pharmaceuticals, Inc - Expected Profit|CervoMed Inc. - Projected Future Earnings|Company Profit Forecast Alterity Therapeutics ATHE|clene.com (CLNN) - Expected Profit|Net Profit Forecast PEPG|JUNS (Jupiter Neurosciences) - Projected Future Earnings|Expected Net Profit Relmada Corp RLMD|Future Profit ANVS (Annovis Bio, Inc.)|Projected Future Earnings gracetx.com (GRCE)|Expected Profit Firefly Neuroscience AIFF|Expected Net Income KLTO|NRSN - Expected Profit|Expected Net Profit Reviva Pharmaceuticals, Inc.|MTVA: Projected Future Earnings|NRXS (neuraxis.com) - Expected Profit|Expected Profit Helius Medical Technologies, Inc.|PASG: Expected Net Income|Projected Future Earnings NEUP|Projected Future Earnings Minerva (NERV)|Projected Future Earnings ATHA (Athira Pharma, Inc.)|Company Profit Forecast addextherapeutics.com (ADXN)|ALZN - Expected Profit|CYCN (Cyclerion Therapeutics) - Net Profit Forecast|protagenic.com (PTIX) - Expected Profit|KTTA - Company Profit Forecast|Future Profit CRGT|ATXI (avenuetx.com) - Future Net Profit|Expected Profit Cara Therapeutics (CARA)|CHRO - Expected Net Profit|Expected Profit Eliem Therapeutics Inc. ELYM|Expected Net Income ITCI|LBPH - Expected Profit|marinuspharma.com (MRNS) - Future Profit|NKGN (NKGen Biotech) - Future Profit|NeuroBo Pharmaceuticals Inc - Expected Net Income|SAGE (Sage Therapeutics, Inc) - Projected Future Earnings|Future Profit Synaptogenix, Inc (SNPX)|Projected Future Earnings TRVN|VIGL - Expected Net Profit|Expected Profit Anew Medical, Inc. WENA|Cerevel Therapeutics Inc - Expected Profit
